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Abstract: Adipose-derived stem cells (ADSCs) have been implicated in tumor growth and metastasis
in breast cancer. ADSCs exhibit tumor tropism, and are of increasing clinical relevance due to
the autologous fat grafting for breast reconstruction. Although we have previously shown that
a high level of the adipocytokine visfatin in human breast cancer tissues correlated with tumor
progression mediated by cAbl and STAT3, the effects of visfatin in the tumor microenvironment are
unclear. To understand how visfatin modulates breast cancer within the tumor-stromal environment,
we examined determinants of breast cancer progression using a visfatin-primed ADSCs-tumor
co-culture model. ADSCs were isolated from tumor-free adipose tissue adjacent to breast tumors.
ADSCs were treated with or without visfatin for 48 h and then collected for co-culture with breast
cancer cell line MDA-MB-231 for 72 h in a transwell system. We found that the MDA-MB-231 cells
co-cultured with visfatin-treated ADSCs (vADSCs) had higher levels of cell viability, anchorage
independent growth, migration, invasion, and tumorsphere formation than that co-cultured with
untreated ADSCs (uADSCs). Growth differentiation factor 15 (GDF15) upregulation was found in the
co-culture conditioned medium, with GDF15 neutralizing antibody blocking the promoting effect on
MDA-MB-231 in co-culture. In addition, a GDF15-induced AKT pathway was found in MDA-MB-231
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and treatment with PI3K/AKT inhibitor also reversed the promoting effect. In an orthotopic xenograft
mouse model, MDA-MB-231 co-injected with vADSCs formed a larger tumor mass than with uADSCs.
Positive correlations were noted between visfatin, GDF15, and phosphor-AKT expressions in human
breast cancer specimens. In conclusion, visfatin activated GDF15-AKT pathway mediated via ADSCs
to facilitate breast cancer progression.
Keywords: breast cancer; visfatin; adipose-derived stem cells (ADSCs); GDF15
1. Introduction
Breast cancer is one of the commonest cancers worldwide, with 2.09 million cases annually [1].
Obesity is increasingly seen as one of the most important modifiable risk factors in breast cancer,
with epidemiological studies indicating that obese, postmenopausal women exhibit both an increased
incidence [2] and poorer prognostic outcomes [3]. The breast itself consists of variable amounts
of adipocytes (approximately 90%) and epithelial tissue (10%) [4], with adipose tissue no longer
considered an inert tissue due to accumulating evidence regarding the interplay between cancer cells
and stromal cells in breast cancer.
Recently, adipose-derived stem cells (ADSCs) have received attention for their role in the biology
of breast cancer. ADSCs are increasingly relevant not only due to rising levels of population obesity,
but also due to the advent of autologous fat transfer as a method of breast reconstruction after cancer
surgery. Of particular concern is the use of ADSC enrichment in fat grafting techniques that are
designed to increase percentage fat engraftment [5,6]. ADSCs may influence breast cancer through
several distinct pathways. The breast cancer microenvironment may induce the differentiation of
ADSCs into carcinoma-associated fibroblasts that promote tumor growth, with more pronounced
effects noted in ADSCs from obese patients [7,8]. ADSCs may also produce multiple factors including
insulin-like growth factor (IGF), hepatocyte growth factor (HGF), VEGF, IL8, and TGFβ [9–13], and may
induce epithelial-mesenchymal transition (EMT), promoting tumor migration and metastases [14,15].
However, at present, it remains unclear how the ADSC tumor-stromal interaction may be further
modulated by factors secreted in the tumor microenvironment.
Obesity-related cytokines, also known as adipocytokines, have been identified as one such
factor [16,17]. Adipose tissues emit a variety of adipocytokines that act through autocrine, paracrine
and endocrine manners to influence tumor cell proliferation, migration and invasion in breast
cancer [18–20]. Among adipocytokines, visfatin, also known as nicotinamide phosphoribosyltransferase
(NAMPT) or pre-B-cell colony-enhancing factor (PBEF), regulates growth, apoptosis, inflammation,
and angiogenesis in mammalian cells [21]. High levels of visfatin in the tumor microenvironment
have been shown to be associated with an increased risk of cancer progression and malignant cancer
behavior in breast cancer patients [4,22,23]. Intracellular visfatin functions as a rate-limiting enzyme in
the biosynthesis of nicotinamide adenine dinucleotide (NAD), whilst extracellular visfatin exhibits
enzyme-like activity on extracellular NAD formation as well as cytokine-like activity through a putative
receptor-mediated pathway [21]. Both intracellular and extracellular visfatin have been implicated
in tumor development [24,25], with promotion of cell growth via a NF-κB/Notch1 pathway in breast
cancer cells, and facilitation of metastasis and angiogenesis via PI3K/Akt, MAPK and c-Abl/STAT3
signaling pathways in human endothelial cells, macrophages and breast cancer cells [23,26,27].
Our prior studies showed that a high level of visfatin in human breast cancer tissues correlated
with tumor progression mediated by cAbl and STAT3, using breast cancer cell lines. To understand how
visfatin modulates breast cancer within the tumor-stromal environment, we examined determinants of
breast cancer progression using a unique visfatin primed ADSC tumor co-culture model. This is the
first description of an adipocytokine-ADSC-breast cancer co-culture model that more closely mimics
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the breast tumor microenvironment. Here, we show that visfatin can act via mechanistically pathways
distinct from those previously discovered using tumor cell line models in isolation [23].
2. Results
2.1. Visfatin-Treated ADSCs Promoted the Viability, Anchorage Independent Growth, Migration, Invasion, and
Tumorsphere Formation of Breast Cancer Cells
Previous study showed that visfatin enhanced the metastasis of breast cancer cells [22,23] Here,
we investigated whether visfatin stimulates ADSCs to promote the breast cancer progression. Using
ADSCs isolated from adipose tissues adjacent to breast tumors of breast cancer patients, we were
able to demonstrate that the isolated ADSCs showed plastic adherence, expressed mesenchymal and
stemness markers and displayed multipotency in both flow cytometry (positive for CD90, CD105, and
CD44, and negative for CD34 and CD45) and differentiation assays for adipogenesis, osteogenesis, and
chondrogenesis (Figure 1).
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phenotype in cancer cells, the expression of EMT-related proteins of MDA-MB-231 co-culture were 
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to uADSCs (Figure 2E). Since tumorsphere formation is associated with cancer stemness, the 
Figure 1. Identification of ADSCs. (A) ADSCs were isolated from the adipose ti sue of breast tumors.
fter t o to three pass ges, the expressions of ADSCs markers (CD90FIT , CD105PE, and CD44FITC)
and the lack of CD34PE and CD45FITC were confirmed by flow cytometry. (B) The differentiation
ability of ADSCs was tested by adipogenesis, osteogenesis, and chondrogenesis.
The ADSCs with 3–6 passages underwent pre-treatment with visfatin at 50 or 100 ng/mL,
which was similar to the medium or high level of breast cancer patients, respectively [23], for 48 h.
Then, MDA-MB-231 cells were co-cultured with the visfatin-pretreated ADSCs (vADSCs) or untreated
ADSCs (uADSCs) indirectly in a transwell system for 72 h. ADSCs were obtained from 10 breast
cancer patients, with visfatin-treatment having a significant promoting effect on MDA-MB-231 cell
migration (Figure S1). We chose three ADSCs which promoted greater than 1.5-fold cell migration
of MDA-MB-231 to evaluate their effects on the viability, anchorage independent growth, migration
and invasion of MDA-MB-231. We found that co-culture with vADSCs promoted the cell viability of
MDA-MB-231 at different time points compared to uADSCs (Figure 2A). Also, vADSCs stimulated
greater colony formation of MDA-MB-231 compared to uADSCs (Figure 2B). Meanwhile, the cell
migration, invasion, and tumorsphere formation of MDA-MB-231 or MCF7 were enhanced after
co-culturing with vADSCs compared with co-culturing with uADSCs (Figure 2C,D). Since the process
of epithelial-mesenchymal transition (EMT) leads to acquisition of a migratory and invasive phenotype
in cancer cells, the expression of EMT-related proteins of MDA-MB-231 co-culture were analyzed.
We found that the mesenchymal markers of ZEB, Snail, and β-catenin were increased and the epithelial
marker ZO-1 was decreased in MDA-MB-231 cells co-cultured with vADSCs compared to uADSCs
(Figure 2E). Since tumorsphere formation is associated with cancer stemness, the expressions of
stemness-related proteins were also assessed. We found that the expression of Nanog and Oct4 were
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upregulated when MDA-MB-231 cells were co-cultured with vADSCs compared to uADSCs (Figure 2E).
To clarify the effect of the breast cancer microenvironment on neighboring ADSCs, we tested the
response of the ADSCs isolated from non-cancer patients who underwent cosmetic breast surgery to
visfatin treatment. The results showed that tumor-free ADSCs did not respond to visfatin treatment
to enhance the cell migration of MDA-MB-231 (Figure S2). This suggested that the breast cancer
microenvironment may alter the response of ADSCs to visfatin. These results suggested that visfatin
can drive the neighboring ADSCs to stimulate malignant behaviors in breast cancer cells.
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Figure 2. Visfatin-primed ADSCs (vADSCs) promoted the viability, anchorage independent growth,
migration, invasion, epithelial-mesenchymal transition (EMT), and stemness property of breast cancer
cells. ADSCs were treated with or without visfatin, noted as vADSCs or uADSCs, respectively, at 50
and 100 ng/mL for 48 h. Then, MDA-MB-231 cells were indirectly co-cultured with uADSCs or vADSCs
in a transwell system for 72 h, noted as Ctrl or V50 and V100. (A) After that, the MDA-MB-231 collected
from the co-culture were seeded in 96-well plate for 24, 48, and 72 h for analyzing the cell viability by
XTT assay. (B) The collected MDA-MB-231 cells were seeded in a six-well plate with Noble agar for
21 days to analyze the anchorage independent growth by soft agar colony formation assay. (C) The
collected MDA-MB-231 cells were seeded in a 24-well transwell plate coated with or without the
Matrigel for performing migration or invasion assay, respectively. (D) The collected MDA-MB-231 cells
were seeded in a 96-well low binding plate for tumorsphere formation. (E) The collected MDA-MB-231
cells were analyzed for the expressions of EMT- and stemness-related proteins by western blotting.
MDA-MB-231 cells only were noted as Alone. Representative images of western blot shown. The result
was quantified and present as histogram. All experiments were performed in triplicate. The statistical
differences were calculated by t-test from three independent experiments. p-values < 0.05 or < 0.01
were marked with “*” or “**”, respectively.
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2.2. Growth Differentiation Factor 15 (GDF15) Plays a Crucial Role in Promoting Malignant Behaviors
To investigate the mechanism of regulation, we used a cytokine array kit to analyze the condition
medium (CM) of the co-culture. We found that the signal of growth differentiation factor 15 (GDF15)
was stronger in the co-culture CM of vADSC and MDA-MB-231 than that of uADSCs and MDA-MB-231.
This upregulation of GDF15 in the CM was confirmed by ELISA. GDF15 expression in the cells of
uADSCs, vADSCs, and MDA-MB-231 collected from the co-culture system was examined by Western
blotting. We found a slight increase in GDF15 expression in vADSCs but not in MDA-MB-231,
which implied that GDF15 was produced by vADSCs (Figure 3B). The increased expression of GDF15
in ADSCs treated with visfatin was also confirmed by western blotting (Figure S3). Furthermore,
we treated MDA-MB-231 cell with GDF15 recombinant proteins and found enhancement of migration
and invasion of MDA-MB-231 cells (Figure 3C). To confirm the role of GDF15 in the CM, GDF15
neutralizing antibody was added to the co-culture of vADSC and MDA-MB-231. This reversed the
enhancement of migration and invasion of MDA-MB-231 by co-culture (Figure 3D). Since GDF15 has
been reported to activate the AKT pathway [28,29], we examined the expression of phosphor-AKT
(pAKT) of MDA-MB-231 and found its induction within two hours after GDF15 treatment (Figure 3E).
We checked the level of pAKT in MDA-MB-231 after co-culture and found it was higher in co-culture
with vADSCs than with uADSCs (Figure 3F). By incubating with the PI3K/AKT inhibitor wortmannin
in the co-culture system, the enhancement of MDA-MB-231 cell migration by ADSCs was inhibited
(Figure 3G).
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and V100 group) or untreated ADSCs (Ctrl group), the CM was collected and analyzed by using
a cytokine array kit. (B) The expression of GDF15 in the co-cultured CM was validated by ELISA
represented in a histogram. The ADSCs and MDA-MB-231 cells collected from the co-culture system
were extracted for cell lysate to analyze the GDF15 expression by western blotting. (C) The migration and
invasion of MDA-MB-231 treated with GDF15 at various concentrations for 48 h were evaluated by using
a transwell system. (D) The indirect co-culture was performed in the presence or absence of the GDF15
neutralizing antibody of for three days. After that, the migration and invasion of the MDA-MB-231
cells collected from the co-culture were evaluated in a transwell system. (E) The expression of
phosphor-AKT (pAKT) of MDA-MB-231 treated with GDF15 (50 ng/mL) at different time point was
detected by western blotting. (F) The pAKT was detected in the MDA-MB-231 cells from the co-culture
by western blotting. (G) After the three-day co-culture in the presence or absence of the wortmannin
(400 nM), the MDA-MB-231 cells were collected from the co-culture for performing the migration assay.
All experiments were performed in triplicate.
Angiogenesis was assessed with HUVEC tube formation assay, by co-culture of HUVECs with
vADSCs or uADSCs. We found vADSCs stimulated tube formation of HUVECs better than uADSCs
(Figure 4A), but this effect was not abolished by GDF15 neutralizing antibody in co-culture with vADSCs
(Figure 4B). These findings suggested that the generation of GDF15 in co-culture of MDA-MB-231
and vADSCs play a key role in promoting MDA-MB-231 malignant behaviors via pAKT pathway,
independent of its effects on angiogenesis.
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2.3. Visfatin-Pretreated ADSCs Enhanced Breast Cancer Tumor Growth and Metastasis in a Xenograft Mouse
Model
To explore the effect of visfatin-pretreated ADSCs (vADSCs) on MDA-MB-231 tumor formation
in vivo, we used an orthotopic xenograft nude mouse model formed by co-injecting MDA-MB-231 and
vADSCs or untreated ADSCs (uADSCs), noted as V50 or Ctrl, respectively, into the mammary fat pads
subcutaneously. This result showed in significantly larger tumor formation with V50 versus Ctrl at
week 8 (Figure 5A). After sacrificing the mice, the weight of V50 tumors was found to be significantly
higher than that of Ctrl tumors (Figure 5B). The tumor tissues were collected to analyze related
protein expressions by immunohistochemistry. Expression of GDF15, β-catenin, pAKT, and CD31
were significantly higher in V50 tumors than in Ctrl tumors (Figure 5C). Furthermore, the effect on
tumor metastasis was examined by using mouse tail-vein injection model. The luciferase-expressing
MDA-MB-231 cells were collected to inject into the tail vein of NOD/SCID mice after co-culturing
with vADSCs or uADSCs for three days, noted as V50 or Ctrl, respectively. The result showed that
co-cultured with vADSCs increased lung metastasis of the luciferase-expressing MDA-MB-231 cells
more than co-cultured with uADSCs, determined by photo flux reading at week 4 (Figure 5D).
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2.4. Correlation Analysis Between the Expression of Visfatin, GDF15, and pAKT in the Specimen of Breast
Cancer Patients
To validate the correlation between the expression of visfatin, GDF15, and pAKT in breast cancer
specimens, the immunohistochemistry of these three proteins was assayed in human breast cancer tissue
microarray samples (Figure 6A). Staining results were captured and analyzed with TissueFAXS 3.5
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and HistoQuest Analysis Software. Correlation was analyzed with the Pearson correlation coefficient
(https://www.socscistatistics.com/tests/pearson/default2.aspx). The results showed that visfatin and
GDF15 had a positive correlation (r = 0.4485, p < 0.001), GDF15 and pAKT had a positive correlation
(r = 0.3002, p = 0.002), and visfatin and pAKT had a positive correlation (r = 0.3552, p < 0.001) (Figure 6B).
Further, we examined the serum levels of visfatin and GDF15 of breast cancer patients by ELISA.
We found that visfatin and GDF15 had a positive correlation (r = 0.2513, p = 0.005) in the peripheral
blood of the breast cancer patients (Figure 6C). We also analyzed the Oncomine database and found
the expression level of GDF15 transcript was significantly higher in invasive ductal breast carcinoma
tissues than that in normal breast tissues (Figure S4).
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Figure 6. The expressions of visfatin, GDF15, and pAKT in the specimens from breast cancer patients.
(A) The expressions of visfatin, GDF15, and pAKT in breast cancer tissue microarray (n = 96) were
detected by immunohistochemistry. The representative images of high expression levels (No. 1) and
low expression levels (No. 2) were shown. The IHC score was calculated by multiplying the percentage
of positive cells by the intensity, which was identified using HistoQuest Analysis Software. (B) The
correlations between visfatin, GDF15, and pAKT according to the IHC score were calculated by using
the online Pearson correlation coefficient calculator. (C) The correlation of serum levels of GDF15 and
visfatin of breast cancer patients (n = 120) determined by ELISA was also calculated by using the online
Pearson correlation coefficient calculator.
3. Discussion
3.1. Adipocytokines, ADSCs and the Tumor Microenvironment
The data presented here add to a growing body of literature indicating that stromal-tumor
interactions are of profound significance in breast cancer, and specifically this is the fir study o use
a adipocytokine-ADSCs-tumor cell line co-culture model. Her , we show tha visfatin can act via
mechanistically distinct pathways from th se previously discovered using tumor cell line models
in isolat on [23], and that these newly discovered pathway are mediated via ADSCs in the tumor
microenvironment (Figure 7). This may hav significant future implications on the relevance f
us ng tumor cell lines in isolation in breast cancer research. Furthermore, this study also suggests a
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re-evaluation of factors that may affect ADSCs in the tumor micro-environment, including hormonal
therapy, radiotherapy, and autologous fat grafting in breast cancer and obesity.Cancers 2019, 11, x FOR PEER REVIEW 9 of 18 
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Figure 7. Visfatin mediates its effects both directly via cAbl/STAT3 and indirectly mediated by ADSCs
via GDF15/AKT on promoting malignant behavior in breast cancer. Previously, we discovered visfatin
mainly produced by adipocytes promoted breast cancer cells directly through activation of c-Abl and
STAT3, which was blocked by Imatinib and Stattic inhibitor, respectively (black arrow). In this study,
we showed that visfatin can act via an indirect pathway by priming ADSCs, which may be recruited
from the adipose tissue to tumor site or generated from autologous fat transfer, to produce GDF15
that stimulated AKT activation in breast cancer cells to promote malignant behaviors (white arrow).
The effect can be blocked by the treatment of GDF15 neutralizing Ab or Wortmannin inhibitor.
Obesity may influence breast cancer progression through alteration of systemic metabolism,
inflammatory response, growth factor signaling, and angiogenesis. A key component in this process is
ADSCs, which are present in breast tissue at approximately 0.6 × 106 ADSCs per gram of tissue [30].
During obesity progression, adipose tissue expansion leads to adipocytokine overproduction and ADSC
proliferation. The increased ADSCs may traffic from the adipose tissue to tumor to accelerate cancer
progression [31–33]. A mouse model of diet-induced obese (DIO) has suggested that obesity-induced
secretion of CXCL1 by cancer cells creates a chemotactic gradient that enables ADSCs trafficking to
tumors via CXCR1 [34]. The inflammatory cytokines MIP-1δ/MIP-3α [35], and PDGF BB/PDGR-B
have also been implicated in ADSCs tumor tropism [36], with PDGF BB expression levels elevated
after radiotherapy treatment. Furthermore, systemic migration of ADSCs to tumor sites has been
demonstrated with fluorescence labelled ADSCs tail vein injection mouse models [35]. In the present
study, we found that visfatin-treated ADSCs promoted malignant behaviors and tumor formation in
breast cancer cells via a GDF15-induced AKT pathway. Previous data has demonstrated that co-injection
of ADSCs with MDA-MB-231 stimulated greater tumor volume in mammary fat pad of nude mice
than MDA-MB-231 injection alone [15]. Here we co-cultured MDA-MB-231 with ADSCs in a transwell,
and co-injected MDA-MB-231 with ADSCs into a mouse mammary fat pad to mimic breast tumor
recruitment of ADSCs. ADSCs pretreated with visfatin had a more significant effect on MDA-MB-231
tumor formation than untreated ADSCs, implying that ADSCs immersed in a visfatin-rich environment
of obese adipose tissue may enhance its promoting effect on breast cancer progression.
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3.2. Visfatin-Primed ADSCs Promote Tumor Stemness and EMT through GDF15-pAKT Pathway
Exogenous administration of visfatin can stimulate human leukocytes to produce IL-1β, TNF-α,
and IL-6 [37], or induce the secretion of IL-6, IL-8, and MCP-1 during osteogenic and adipogenic
differentiation of MSCs [38]. Visfatin may also activate HUVEC to up-regulate the expression of VEGF
and MMPs [39]. In the present study, we found that co-culture of CM of MDA-MB-231 and vADSCs
increased GDF15 expression, which was vADSC specific. GDF15 (also known as MIC-1, NAG-1, PLAB,
PTGFB) is a cytokine of the TGF-β superfamily that is up-regulated in response to inflammation,
cardiovascular disease, obesity, and cancer [40–42]. GDF15 may be involved in the proliferation,
migration, invasion, and angiogenesis of tumors, with with recent research finding GDF15 promoted
EMT and invasion of breast cancers [43], and supported the maintenance of breast cancer stem-like
cells [44]. Furthermore, GDF15 promoted the proliferation of cervical cancer cells by interaction
with ErB2 to activate PI3K/AKT and MAPK/ERK pathways [28], and enhanced the migration of
pancreatic cancer cells via an AKT pathway [29]. Similarly, our study found that increased pAKT levels
in MDA-MB-231 co-culture were responsible for tumor cell migration-promoting effects. This was
reversed with GDF15 neutralizing antibody and wortmannin inhibitor. Although GDF15 has been
reported by others to promote angiogenesis in tube formation assays with HUVEC cells [45], we found
that treatment with GDF15 neutralizing antibody did not inhibit the angiogenic effect from vADSCs.
This implied that a GDF15 independent pathway may be involved in vADSCs related angiogenesis.
Although this was not the focus of our study, mechanisms described for ADSCs related angiogenesis
include elevated VEGF production leading to angiogenic sprouting, pericyte differentiation, and the
IL-6 endothelin 1 pathway [46,47]. Collectively our findings suggested that vADSCs may mediate
breast cancer EMT and stemness via a GDF15-induced AKT pathway, and promote angiogenesis
through a GDF15 independent pathway.
GDF15 protein expression is markedly increased in various types of cancer biopsies including
breast cancer [43,48–51], with our analysis of the Oncomine database also noting significantly higher
GDF15 mRNA expression levels in breast cancer tissues than normal breast tissues. In this study,
we also showed a positive correlation between GDF15 and visfatin expression in breast tumors. As an
association between visfatin and breast cancer progression has been previously established [22,23,52],
GDF15 may likewise be used as a potential biomarker in breast cancer. Recently, the GDNF-family
receptor α-like (GFRAL) protein was identified as a receptor for GDF15, with increased pAKT elicited
by GDF15 in GFRAL-overexpressed HEK293 cell lines [53–55]. GFRAL has been proposed as a drug
target for appetite-related disorders, and similarly may provide a future therapeutic strategy in breast
cancer. In this regard, GFRAL may act as both an upstream and downstream therapeutic target,
with appetite suppression reducing both obesity and correlated visfatin levels, and GDF15 inhibition
reducing downstream visfatin mediated pAKT. An obese mouse-orthotopic breast cancer cell line
model would act as an in-vivo analogue, allowing differential analysis of these effects.
3.3. Visfatin-ADSC-Tumor Co-Culture Is a Model for Future Breast Tumor Microenvironment Research
Currently, a significant proportion of breast cancer research is carried out on breast cancer cell
lines that are not representative of the breast tumor microenvironment and cellular diversity, with some
common cell lines derived from malignant pleural effusions. Weigand et al and others [56], suggest
that only an ensemble of tissue including ADSCs, mammary epithelial cells and mesenychmal cells,
can represent breast tumor tissue adequately. Our study is the first adipocytokine-ADSC-cancer line
co-culture model in breast cancer, and the first to demonstrate that visfatin can act via mechanistically
distinct pathways from those previously found using tumor cell line models in isolation [23]. Therefore,
basing breast cancer research on tumor cell lineage models alone, may result in incomplete elucidation
of tumor pathways with a potentially reduced efficacy of translational clinical therapies.
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4. Materials and Methods
4.1. Cell Culture
The human breast carcinoma cell lines MCF7 and MDA-MB-231, and human umbilical vein
endothelial cell line HUVEC were purchased from the Bioresource Collection and Research Center
(BCRC, Hsinchu, Taiwan). The luciferase-expressing MDA-MB-231 cells were kindly provided
by Prof. Wen-Chun Hung, National Health Research Institutes, Taiwan. MCF-7, MDA-MB-231,
and luciferase-expressing MDA-MB-231 cells were cultured in DMEM medium (12100046, Thermo
Fisher Scientific, Waltham, MA, USA) supplemented with 10% FBS (Biological Industries, Cromwell,
CT, USA) and 1% antibiotic-antimycotic (15240062, Thermo Fisher Scientific). HUVEC was cultured
in Media 199 (11150059, Thermo Fisher Scientific) with 10% FBS (Thermo Fisher Scientific), 30ug/ml
endothelial cell growth supplement (ECGS) (E2759, Sigma-Aldrich, St Louis, MO, USA), and 1%
antibiotic-antimycotic (15240062, Thermo Fisher Scientific). Human ADSCs isolation was modified
based on previous article [57]. In brief, the ADSCs were isolated from tumor-free adipose tissue
adjacent to the breast tumor of 10 breast cancer patients with invasive ductal carcinoma that underwent
mastectomy. The patients signed informed consent document approved by the Institutional Review
Board of Kaohsiung Medical University Hospital. The adipose tissues were cut into small pieces using
scissors, and the extracellular matrix digested with 5 mg/mL collagenase type II (C6885, Sigma-Aldrich)
at 37 ◦C for 1 h with gentle shaking. The cell solution was passed through 100 µm cell strainer (Falcon
352360, Corning, NY, USA). The filtrate was centrifuged at 500 g for 10 min. The cell pellet was washed
with PBS and cultured with alpha minimum essential medium (α-MEM) (Hyclone SH30526.02, GE
Healthcare, Pittsburgh, PA, USA) containing 5% UltraGRO (HPCPLCRL10, AventaCell, Atlanta, GA,
USA). The total number of passages for experiment was up to seven passages. All cells were cultured
with 5% CO2 at 37 ◦C in a humidified incubator.
4.2. ADSCs Differentiation
The differentiation of ADSCs into three cell lineages was performed according to a previous
protocol with modification. For adipogenic differentiation, ADSCs were cultured in adipogenic medium
(DMEM supplemented with 10% FBS, 100 µM indomethacin (I7378, Sigma-Aldrich), 10 µg/mL insulin
(I3536, Sigma-Aldrich), 1 µM dexamethasone (D4902, Sigma-Aldrich), 0.5 mM isobutylmethylxanthine
(IBMX) (I5879, Sigma-Aldrich), 100 U/mL penicillin, and 100 mg/mL streptomycin) for 12 days.
Then, the cells were stained with Oil Red-O (O0625, Sigma-Aldrich) to examine the lipid accumulation.
For osteogenic differentiation, ADSCs were cultured with osteogenic medium (DMEM supplemented
with 10% FBS 10 mM β-glycerophosphate (G9422, Sigma-Aldrich), 0.05 mM ascorbate-2-phosphate
(A8960, Sigma-Aldrich), 100 nM dexamethasone, 100 U/mL penicillin, and 100 mg/mL streptomycin)
for 2 weeks. After that, the cells were stained with von Kossa (1003620001, Sigma-Aldrich) for
evaluation. For chondrogenic differentiation, ADSCs were cultured with chondrogenic medium
(DMEM supplemented with 10% FBS, 6.25 µg/mL insulin, 10 ng/mL TGF-β1 (100-21, Peprotech, Rocky
Hill, NJ, USA), and 50 µM L-ascorbic-acid-2-phosphate (A8960, Sigma-Aldrich)) for 2 weeks. Then,
the cells were stained with Alcian blue (A5268, Sigma-Aldrich) to examine the sulfated proteoglycan-rich
matrix. All the culture medium was replaced every 2 or 3 days throughout the period of differentiation.
4.3. Flow Cytometry
For characterizing the ADSCs, the cells were collected and incubated with fluorochrome-conjugated
antibodies against CD44 (11-0441-82, Thermo Fisher Scientific), CD90 (11-0909-42, Thermo Fisher
Scientific), CD34 (12-0349-42, Thermo Fisher Scientific), CD45 (11-0459-42, Thermo Fisher Scientific),
and CD105 (12-1057-42, Thermo Fisher Scientific). The stained cells were washed with PBS and
suspended in sorting buffer before analysis by FC500 Flow Cytometer (Beckman Coulter, Brea, CA,
USA).
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4.4. Indirect Co-Culture
After 3–6 passages, ADSCs were seeded in 6-well plate (2 × 105 cells/well) overnight and then
underwent serum starvation for 24 h. The ADSCs were treated with or without visfatin, noted
as vADSCs or uADSCs, respectively, at 50 or 100 ng/mL, which mimic the physiological level of
breast cancer patients [23], in α-MEM containing 0.5% UltraGRO for 48 h. After that, the indirect
co-culture in a transwell was performed. The vADSCs or uADSCs were collected to seed in the inserts
(2 × 104 cells/insert) of 24-well transwell plate (0.4 µm pores, Corning) with 0.5% UltraGRO α-MEM.
The MDA-MB-231 or HUVEC cells were seeded in the lower wells (6 × 104 cells/well) with 1% FBS
DMEM or 1% FBS Media 199, respectively. For testing the regulation mechanism, GDF15 neutralizing
antibody (5 µg/mL) (MAB957-100, R&D systems, Minneapolis, MN, USA) or the PI3K/AKT inhibitor
wortmannin (400 nM) (W1628, Sigma-Aldrich) were added in the lower well. After 72-hour co-culture,
the MDA-MB-231 cells were collected for performing cell proliferation assay, soft agar colony formation
assay, migration, invasion, and tumorsphere formation assays. The HUVEC cells were collected for
tube formation assay.
4.5. Cell Proliferation Assay
The treated MDA-MB-231 cells were seeded in 96-well plate (2000 cells/well) and
cultured with DMEM containing with 10% FBS for 24~72 h. After that, XTT (2,3-Bis-(2-
methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide, X4251, Sigma-Aldrich) was applied
into wells with PMS (Phenazine methosulfate, P9625, Sigma-Aldrich). The absorbance (A1) of each
well was measured at a wavelength of 475 nm and the nonspecific reading (A2) was measured at
660 nm. The proliferation rates were calculated as ∆A = A1 − A2.
4.6. Soft Agar Colony Formation Assay
A 6-well culture plates containing 0.5% agarose as solid bases were prepared. The treated
MDA-MB-231 cells suspended with 10% FBS DMEM in 0.35% agarose was added to top of the solid
base. The cells were cultured for 14 days to form colonies. Colonies were stained with 0.25% crystal
violet, and the colonies with diameter above 1 mm were analyzed using a stereoscope dissecting
microscope. The amounts of colonies were analyzed using ImageJ software (National Institute of
Mental Health, Bethesda, MD, USA).
4.7. Cell Migration and Invasion Assays
For performing cell invasion or migration assay, the MDA-MB-231 cells collected from the
co-culture system or treated with human recombinant GDF15 (10936-H01H, Sino Biological, Wayne,
PA, USA) were suspended in serum-free DMEM and transferred to the 24-well transwell inserts coated
with or without Matrigel, respectively (8 µm pores, Corning). The lower wells were added with DMEM
containing with 10% FBS. After 24-hour incubation, cells in the top chamber were removed by cotton
swabs. The membrane-trapped cells were fixed, stained with crystal violet and observed using a light
microscope. The amounts of migrated cells were analyzed using ImageJ software.
4.8. Tumorsphere Formation Assay
After the indirect co-culture, MDA-MB-231 or MCF7 were collected to suspended in the phenol
red-free DMEM (21063029, Thermo Fisher Scientific) supplemented with recombinant human fibroblast
growth factor basic (20 ng/ml) (100-18C, Peprotech), recombinant human epidermal growth factor
(20 ng/mL) (GMP100-15, Peprotech), insulin (10 µg/mL), and 1 × B27 (17504044, Thermo Fisher
Scientific). The cells were seeded into an ultra-low attachment 96-well plate (3474, Corning) at a
density of 2000 cells per well and cultured in a humidified incubator with 5% CO2 at 37 ◦C for 7 days.
The amount of tumorspheres with diameter over 50 µm was counted.
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4.9. Tube Formation Assay
Human umbilical cord vein endothelial cells (HUVECs) were treated with the CM of visfatin-treated
ADSCs or indirectly co-cultured with visfatin-treated ADSCs as describe above. Meanwhile, a 96-well
containing 100 µL Matrigel per well (354234, Corning) was first chilled at 4 ◦C overnight. Then,
the Matrigel-containing plate was incubated at 37 ◦C, 5% CO2 for 30 min. After that, the treated
HUVECs were seeded on the Matrigel (1 × 104 cells/well) and incubated for 4 h. The tube formation
was observed by a light microscope and the network length (cells joined from end-end) was analyzed
by ImageJ software.
4.10. Western Blot
The ADSCs and MDA-MB-231 cells collected from the co-culture system or GDF15-treated
MDA-MB-231 cells were lysed with RIPA lysis buffer. Protein concentrations determined using
Bio-Rad protein assay (BIO-RAD, Hercules, CA, USA). Equal amounts of total proteins were subjected
to sodium dodecyl sulfate–polyacrylamide gel electrophoresis, and transferred to nitrocellulose
membrane (IBFP0785C, Merck Millipore, Burlington, MA, USA). After blocking with 5% non-fat milk,
the membrane was incubated with primary antibodies at 4 ◦C overnight. Primary antibodies
used in western blotting included β-actin (GTX109639, GeneTex, Hsinchu, Taiwan), α-tubulin
(GTX112141), ZEB1 (GTX105278), Snail (GTX82509), ZO-1 (GTX108627), Nanog (GTX100863), Oct4
(GTX101497), β-catenin (ab16051, Abcam, Cambridge, MA, USA), GDF15 (PAB31426, Abnova, Taipei,
Taiwan), phosphor-AKT (4060, Cell Signaling, Danvers, MA, USA), and AKT (4691, Cell Signaling).
Immunoreactive proteins were detected after incubation with horseradish peroxidase-conjugated
secondary antibody (31430, Thermo Scientific) for 1 h at room temperature. The immunoblots
were visualized using chemiluminescence reagent (WBKLS0500, Merck Millipore) and quantified by
ChemiDoc XRS+ imaging system (BIO-RAD).
4.11. Cytokine Array Analysis and ELISA
To explore the cytokine expression profile in the medium of the indirect co-culture of MDA-MB-231
and resistin-pretreated ADSCs, a Proteome profiler™ human XL cytokine array kit (ARY022, R&D
Systems) was adopted. The expressions of GDF15 in the co-cultured medium and the serum of breast
cancer patients obtained at the Cancer Center of Kaohsiung Medical University Hospital (KMUH)
during the 2003 to 2008 from previous study [22] were detected by using a human GDF15 ELISA kit
(DGD150, R&D Systems). The visfatin expression in the serum of breast cancer patients were detected
by using a human visfatin ELISA kit (DY4335-05, R&D Systems). These kits were used according to
manufacturer’s instructions.
4.12. Animal Study
The animal experiments were conducted in accordance with the Institutional Animal Care
and Utilization Committee of Kaohsiung Medical University, Kaohsiung, Taiwan. The number
of animals used in the experiments was minimized according to the 3Rs. Nude mice
(BALB/cAnN.Cg-Foxn1nu/CrlNarl) aged 6–8 weeks were purchased from the National Laboratory
Animal Center, Taiwan. The nude mice were fed with normal diet under specific pathogen-free
conditions. For orthotopic model, 1 × 106 visfatin-treated ADSCs (vADSCs) or untreated ADSCs
(uADSCs) were co-injected with 2 × 106 MDA-MB-231 cells into the 4th mammary fat pads of
female nude mice. The size of tumor was measured twice a week, and tumor volumes calculated
according to the standard formula: (Width 2 × Length)/2. After 45 to 60 days, the mice were sacrificed
and tumors, organs were collected for evaluation. For metastatic model, the luciferase-expressing
MDA-MB-231 cells were co-cultured with vADSCs or uADSCs for 3 days. After that, 2 × 105
luciferase-expressing MDA-MB-231 cells were collected to inject into the tail vein of NOD/SCID
mice (NOD.CB17-Prkdcscid/NcrCrl; aged 6-8 weeks; National Laboratory Animal Center, Taiwan).
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At week 4, the mice were injected with luciferin and the bioluminescent signal was assessed using an
IVIS50 in vivo imaging system (Xenogen, Alameda, CA, USA). The total flux of IVIS radiance signal
was calculated.
4.13. Immunohistochemistry
The MDA-MB-231 tumors of the orthotopic xenograft mouse model were collected to make
formalin-fixed paraffin-embedded tissue blocks. The tissue microarray slides of human breast cancer
specimens obtained at the Cancer Center of Kaohsiung Medical University Hospital (KMUH) from 2003
to 2008 were generated by previous study [22]. The immunohistochemistry was performed on 5 µm
paraffin sections by using a fully automated Bond-Max System (Leica Microsystems, Wetzlar, Germany).
All staining steps were performed by the automated instrument, according to the manufacturer’s
instructions (Leica Microsystems). The primary antibodies used for this experiment included visfatin
(sc-376336, Santa Cruz, Dallas, Texas), GDF15 (PAB31426), β-catenin (ab16051), and phosphor-AKT
(GTX28932). The staining of the xenograft tumors was determined separately for each specimen by 2
independent experts simultaneously under the same condition. The staining result was calculated
by multiplying the score of percentage of positive cells by the score of staining intensity. The score
of percentage of positive cells was defined as: score 0, 0%; score 1, 1%~25% positive cells; score
2, 26%~50%; score 3, 51%~75%; score 4, 76%~100%. The score of staining intensity was defined
as: score 0, negative; score 1, weak; score 2, moderate; score 3, strong. The staining of the human
breast cancer tissue microarray slides was scanned by using TissueFAXS 3.5 (TissueGnostics, Vienna,
Austria). The percentage of positive cells and the staining intensity were analyzed by using HistoQuest
Analysis Software (TissueGnostics). The staining result was also calculated by multiplying the score of
percentage of positive cells by the score of staining intensity.
4.14. Statistical Analysis
Statistical analysis was performed using the GraphPad Prism 5 software (GraphPad Software
Incorporation, San Diego, CA, USA). All the data were shown as mean ± SEM. Student’s t-test was
used to compare two groups. Significance differences were set as *p < 0.05; ** p < 0.01; *** p < 0.001.
The correlation of proteins expression detected by IHC or ELISA was calculated by using the online
Pearson correlation coefficient calculator (https://www.socscistatistics.com/tests/pearson/default2.aspx).
5. Conclusions
The data presented here support the accumulating evidence supporting the importance
of stromal-tumor interactions in breast cancer. Significantly, this is the first study to use an
adipocytokine-ADSCs-tumor cell line co-culture model. Here, we showed that visfatin can act both
directly on tumor cells and indirectly via ADSCs in the tumor microenvironment. The indirect pathway,
mediated by visfatin-primed ADSCs, promoted tumor stemness and EMT through a GDF15-pAKT
pathway. This study establishes a novel and important model for future stromal-tumor analysis in
breast cancer, and highlights previously unknown therapeutic targets in the GDF15-pAKT pathway.
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visfatin, Figure S4: Analysis of the expression levels of GDF15 transcripts in Oncomine database.
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